<?xml version="1.0" encoding="UTF-8"?>
<p>In summary, these results established that favipiravir can be effective against EBOV in NHPs in a prophylactic setting and with drug concentrations about twice larger than in the JIKI trial,
 <xref rid="psp412510-bib-0047" ref-type="ref">
  <sup>47</sup>
 </xref> and allowed to define new target concentrations for the evaluation in patients. They support the implementation of dose‚Äêranging studies in healthy volunteers to assess the concentrations and the tolerance that could be achieved with doses higher than those used in the JIKI trial.
</p>
